Salud financiera de hoja de balance de AnGes

Salud financiera controles de criterios 3/6

AnGes tiene un patrimonio de los accionistas total de ¥22.2B y una deuda total de ¥1.3B, lo que sitúa su ratio deuda-patrimonio en 5.9%. Sus activos y pasivos totales son ¥25.1B y ¥2.9B respectivamente.

Información clave

5.9%

Ratio deuda-patrimonio

JP¥1.30b

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	JP¥2.92b
Patrimonio	JP¥22.21b
Total pasivo	JP¥2.92b
Activos totales	JP¥25.13b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (¥4.5B) de 4563 superan a sus pasivos a corto plazo (¥1.4B).

Pasivo a largo plazo: Los activos a corto plazo de 4563 (¥4.5B) superan a sus pasivos a largo plazo (¥1.5B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 4563 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 4563 ha crecido de 0% a 5.9% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 4563 tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: 4563 tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 25.6% cada año

Salud financiera de hoja de balance de AnGes

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

New major risk - Financial position

AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: JP¥7.54 loss per share (vs JP¥10.25 loss in 2Q 2023)

New minor risk - Share price stability

AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings released: JP¥9.14 loss per share (vs JP¥15.91 loss in 1Q 2023)

AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024

AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald Europe

New major risk - Share price stability

Full year 2023 earnings released: JP¥37.17 loss per share (vs JP¥94.29 loss in FY 2022)

AnGes, Inc., Annual General Meeting, Mar 28, 2024

Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

New minor risk - Market cap size

AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study

Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study

Third quarter 2023 earnings released: EPS: JP¥0.17 (vs JP¥18.09 loss in 3Q 2022)

Second quarter 2023 earnings released: JP¥10.25 loss per share (vs JP¥29.31 loss in 2Q 2022)

AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.

New major risk - Share price stability

AnGes, Inc. announced that it expects to receive ¥8.481467 million in funding

AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: JP¥15.91 loss per share (vs JP¥19.19 loss in 1Q 2022)

Full year 2022 earnings released: JP¥94.29 loss per share (vs JP¥92.85 loss in FY 2021)

AnGes, Inc., Annual General Meeting, Mar 30, 2023

AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023

Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)

No independent directors

Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)

AnGes, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: JP¥29.31 loss per share (vs JP¥27.72 loss in 2Q 2021)

AnGes, Inc. to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: JP¥19.19 loss per share (vs JP¥24.82 loss in 1Q 2021)

No independent directors

AnGes, Inc. to Report Q1, 2022 Results on May 10, 2022

AnGes, Inc., Annual General Meeting, Mar 30, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: JP¥29.39 loss per share (vs JP¥10.39 loss in 3Q 2020)

Second quarter 2021 earnings released: JP¥27.72 loss per share (vs JP¥8.06 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥24.82 loss per share (vs JP¥8.55 loss in 1Q 2020)

Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)

AnGes, Inc. announced that it has received ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm

AnGes, Inc. announced that it expects to receive ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm

New 90-day low: JP¥1,156

AnGes, Inc., Annual General Meeting, Mar 30, 2021

Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)

AnGes, Inc. to Report Fiscal Year 2020 Results on Feb 15, 2021

AnGes, Inc. (TSE:4563) completed the acquisition of Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others.

AnGes, Inc. and Er-Kim Enter into an Agreement for the Commercialization of Collategene® in Turkey

AnGes, Inc. to Report Q3, 2020 Results on Oct 26, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera